%0 Journal Article
%T Relentless Placoid Chorioretinitis: A Case Series of Successful Tapering of Systemic Immunosuppressants Achieved with Adalimumab
%A Hidetoshi Kawashima
%A Rie Tanaka
%A Shotaro Asano
%A Toshikatsu Kaburaki
%J Archive of "Case Reports in Ophthalmology".
%D 2019
%R 10.1159/000500077
%X Adalimumab, a human anti-tumor necrosis factor-¨» monoclonal antibody, was recently reported to be effective in lowering the risk of recurrence of noninfectious uveitis. This is the first case series of adalimumab administrations for relentless placoid chorioretinitis (RPC) patients
%K Relentless placoid chorioretinitis
%K Adalimumab
%K Uveitis
%K Acute posterior multifocal placoid pigment epitheliopathy
%K Serpiginous choroiditis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528075/